Supplementary Figure 2: Additional data for Fig. 2.

(a) The mutant p53-related proteasome-ubiquitination pathway gene expression is more significantly associated with poor prognosis in breast cancer patients than of the genes from other top pathways derived from the common mutant p53 signature. HR—hazard ratio; logrank P—logrank test P value for the curves comparison (n = 3,458); (b) The high expression of 37 proteasome genes (‘whole proteasome signature’) is associated with the high grade of breast cancer in patients (grades marked 1–3). P value is derived from Mann–Whitney U test (n = 1401). Box plot centre represents the median, box extremes indicate first and third quartile, whiskers extend to the extreme values included in the interval calculated as ±1.58 IQR/sqrt(n) where IQR (interquartile range) is calculated as the third quartile minus the first quartile.; (c) The best recursive feature selection analysis scoring proteasome gene subset (composed of 6 genes, see Methods and Supplementary Table 8) was evaluated for the prognostic correlation in the breast cancer dataset (survival graph as in (a); HR—hazard ratio; logrank P—logrank test P value for the curves comparison, n = 3,458).; (d) The high expression of 37 proteasome genes is associated with the mutant TP53 status in the indicated cancer types (diff—difference in mean signature expression in mutant versus WT p53 status samples; P value is derived from Mann–Whitney U test). Number of patients for each cancer type is indicated below each graph, based on selection in Supplementary Table 14. Box plot centre represents the median, box extremes indicate first and third quartile, whiskers extend to the extreme values included in the interval calculated as ±1.58 IQR/sqrt(n) where IQR (interquartile range) is calculated as the third quartile minus the first quartile.